All published articles of this journal are available on ScienceDirect.
Angiosarcoma Presenting with Spontaneous Hydropneumothorax: Report of a Case and Review of the Literature
Abstract
Angiosarcoma is a rare malignant tumor of soft tissue. Because angiosarcoma originates from endothelial cells, it can occur in any organ and shows aggressive clinical features. Most commonly, angiosarcoma initially presents as a cutaneous lesion. Lung metastasis from scalp angiosarcoma can develop pneumothorax. We report a case of multiorgan involvement of an angiosarcoma, including the scalp, initially presenting with hydropneumothorax. Immunohistochemistry analysis of the cells obtained from the study confirmed the pleural invasion of the angiosarcoma.
INTRODUCTION
Angiosarcoma is a rare aggressive malignancy that has a poor prognosis despite current intensive treatment [1-3]. This tumor can involve multiple organs, including the pleura. Pneumothorax is known to develop from spontaneous rupture of cystic lung lesions in angiosarcoma [4]. In a case of pleural effusion of angiosarcoma, cytology is often negative pathologically under routine stains, and specific immunohistochemical stains can be confirmative [5, 6]. We report a case of angiosarcoma involving the heart, lungs, lymph nodes, scalp, and liver, with malignant pleural effusion.
CASE REPORT
An 83-year-old male visited a local clinic because of sudden chest pain, which developed 1 month prior and became aggravated 1 week previously. He was referred to our hospital for the problem of hydropneumothorax. There was no specific history or familial history of cancer, diabetes, or tuberculosis. He had a 25 pack-year of smoking history. On admission, he appeared acutely ill. His blood pressure was 110/70 mmHg, his pulse rate was 100 beats per minute, and his body temperature was 36.6°C. He showed a poor performance status with an Eastern Cooperative Oncology Group (ECOG) scale score of 3. A mass was palpated on the left supraclavicular area, and it was not tender and firm in consistency. There was a skin lesion of 6 mm in size that was not painful and that was violet and dome shaped in elevation on the left parietal lobe of the skull. Breathing sounds in the left lower lung field were decreased, and no crackles were heard. Other physical findings were negative. On the day of admission, his white blood cell count was 10,400/mm3 with 70% neutrophils and 25% lymphocytes, the hemoglobin level was 12.5 g/dL, and the platelet count was 269,000/mm3. Serum biochemical values were as follows: the blood urea nitrogen level was 23 mg/dL, the creatinine level was 1.6 mg/dL, the total protein level was 5.0 mg/dL, the albumin level was 2.6 mg/dL, and other values were within normal ranges. The levels of neuron-specific enolase, carcinoembryonic antigen, alpha fetoprotein, and CA 19-9 were 14.1 ng/mL, 3.6 ng/mL, 1.9 ng/mL, and 7.5 U/mL, respectively. Initial pleural fluid analysis showed a pH of 7.2, the white blood cell count was 6500/mm3 with 90% eosinophils, 7% lymphocytes, and 1% neutrophils, the total protein level was 3.3 mg/dL, the albumin level was 2.0 mg/dL, the lactic dehydrogenase level was 356 U/L, the adenosine-deaminase level was 29.4 U/L, and the carcinoembryonic antigen level was 6.1 ng/mL. Results for microbiology and cytology in the pleural fluid were negative. On the day of admission, chest radiography showed the finding of hydropneumothorax (Fig. 1). Chest computed tomography (CT) showed multiple tiny nodules and cystic lesions on both lungs, a large amount of pleural effusion with pneumothorax in the left lung, pericardial effusion, enlargement of multiple lymph nodes, and multiple hepatic masses (Fig. 2). Trans-thoracic echocardiography showed a mass with a diameter of 2.0 cm at the right atrioventricular orifice (Fig. 3). Because initial pleural fluid cytology was reported to be negative, excisional biopsy of the cervical lymph nodes was performed. Histopathology revealed that the lymph nodes were almost replaced by the tumor, which formed an anastomosing network of sinusoids lined by hyperchromatic nucleated endothelial cells (Fig. 4). Positron emission tomography-CT showed a standardized uptake value of 14.3 on fluorodeoxyglucose uptake at the left tonsil and also increased uptake at cervical lymph nodes, both lungs, and the liver (Fig. 5). A second thoracentesis revealed pleural metastasis of angiosarcoma under the stains of CD31, CD34, and von Willebrand factor for the atypical cell cluster of the pleural fluid (Fig. 6). Because of the involvement of angiosarcoma in the heart, lungs, pleura, multiple lymph nodes, skin, and liver, the patient was discharged after conservative treatment with consideration of age and current performance status.
DISCUSSION
Angiosarcoma is a malignant cancer that rarely occurs and has a poor prognosis. Angiosarcoma occurs at a male predominance, and mostly affects elderly people, although it can occur at all ages. We reviewed 33 patients from 24 previous reports concerning angiosarcoma with pneumothorax that were based on a PubMed search since 1978. Among the 33 subjects, 21 cases were available for review; 16 subjects were male and 5 were female. The mean age was 68 years, and the most common computed tomography findings were multiple thin-walled cysts and nodules located in the subpleural area (Table 1). As a spontaneous pneumothorax in an aged person, the differential diagnosis was most commonly emphysema (91%), followed by isolated bulla or blebs (4%), mesothelioma (2%), and rare cases of subpleural fibrosis, congenital cystic adenomatoid malformation, tuberculous pleuritis, and angiosarcoma [7].
Serial No* |
No. of Patients |
Age/Sex | Clinical Presentation |
Computed Tomography Findings |
Involved Organs |
Literature |
---|---|---|---|---|---|---|
1 | 1 | 65/m† | Recurrent pneumothorax |
Peripheral solid nodules and infiltrates, pleural effusion |
Scalp | Medicina 2014; 74: 227-8 |
2 | 1 | 62/m | Cough, hemoptysis, pneumothorax |
Multiple thin-walled cysts, a few nodules |
Scalp | Chin Med J 2013; 126(21): 4197 |
3 | 1 | Not available | Pneumothorax | Thin-walled cysts | Scalp | Hum Pathol 2013; 44(12): 2751-9 |
4 | 1 | 71/f † | Bilateral pneumothorax |
Nodular ground glass opacities, multiple diffuse cavities and cysts |
Absent | Am J Respir Crit Care Med 2013; 188(6): 749 |
5 | 1 | 83/m | Pneumothorax | Lung cysts | Scalp | Ann Thorac Surg 2012; 94: e77-8 |
6 | 1 | 83/m | Bilateral pneumothorax |
Thin-walled cysts | Scalp | Chest 2011; 139(6): 1536-9 |
7 | 1 | 68/m | Pneumothorax | Thin-walled cavities | Absent | Kyobu Geka 2008; 61(9): 779-83 |
8 | 10 | Not available | Pneumothorax | Thin-walled cavities and ground glass attenuation |
Scalp | Nihon Kokyuki Gakkai Zasshi 2008; 46(2): 85-91 (case series) |
9 | 1 | 86/m | Bilateral pneumothorax |
Thin-walled cavity | Scalp | Surg Today 2006; 36(10): 919-22 |
10 | 1 | 63/m | Bilateral pneumothorax |
Multiple cystic, cavitary, nodular lesions |
Scalp | J Formos Med Assoc 2006; 105(3): 238-41 |
11 | 1 | 68/m | Pneumothorax | No CT imaging | Scalp | J Korean Med Sci 2003; 18(2): 277-80 |
12 | 1 | 81/f | Pneumothorax | No CT imaging | Scalp | Eur J Dermatol 2001; 11(6): 584-6 |
13 | 1 | 79/f | Pneumothorax | Thin-walled cavity | Scalp | Nihon Kokyuki Gakkai Zasshi 1998; 36(12): 1058-61 |
14 | 1 | Not available | Pneumothorax | No CT imaging | Breast | Chest 1997; 111: 280-5 (review) |
15 | 1 | 80/f | Pneumothorax | Not available | Scalp | Nihon Kyobu Shikkan Gakkai Zasshi 1995; 33(11): 1334-7 |
16 | 1 | 68/m | Bilateral pneumothorax |
Subpleural lesion | Kidney | Chest 1994; 106(4): 1274-6 |
17 | 1 | 57/m | Pneumothorax, hemoptysis |
Cystic lesion | Scalp | RadioGraphics 1993; 13: 1153-5 |
18 | 1 | 69/m | Pneumothorax | Thin-walled cavitary lesions | Scalp | Nihon Kyobu Shikkan Gakkai Zasshi 1993; 31(4): 534-7 |
19 | 1 | 72/m | Bilateral pneumothorax |
Multiple cystic lesions | Scalp | Nihon Kyobu Shikkan Gakkai Zasshi 1993; 31(4): 498-500 |
20 | 1 | 77/m | Bilateral pneumothorax |
No CT imaging | Scalp | Br J Radiol 1990; 63(746): 132-4 |
21 | 1 | 75/m | Bilateral pneumothorax |
Multiple ill-defined peripheral nodules |
Heart | Thorax 1989; 44: 78-9 |
22 | 1 | 44/f | Bilateral pneumothorax |
No CT imaging | Breast | Clin Radiol 1987; 38(2): 201-2 |
23 | 1 | 69/m | Pneumothorax | Multiple cystic nodular lesions in plain radiographs |
Scalp | Virchows Arch A Pathol Anat Histopathol 1987; 412(1): 83-7 |
24 | 1 | 15/m | Pneumothorax | No CT imaging | Heart | Semin Roentgenol 1978; 13(2): 83-4 |
*Number, †male, ‡female.
Radiation therapy is a risk factor for angiosarcoma. In addition, vinyl chloride, thorium dioxide, arsenic, anabolic steroids, neurofibromatosis, Maffucci syndrome, and Klippel-Trenaunay syndrome are known to be risk factors [8-10].
There have been higher diagnostic yields over the years from the development of diagnostic technology, such as pathological technology [8, 9]. Angiosarcoma as an angiogenic tumor can have a definite diagnosis by confirming vascular markers by immunochemistry. Endothelium-specific immune markers include CD31, CD34, and von Willebrand factor. Von Willebrand factor shows high specificity with relatively low sensitivity, while CD34 and CD31 show high specificity and sensitivity [6, 11].
Angiosarcoma occurs at various locations, most commonly at the head and neck, breast, limbs and trunk [8, 9]. With multiple organ involvement at the time of diagnosis, it can be difficult to conclude which area is the primary site. However, regarding pneumothorax, the scalp was the most common primary site of angiosarcoma [12]. This was true in our case, as well as in literature reviews (Table 1). When angiosarcoma invades the lungs, pneumothorax or hemothorax results by forming nodular lesions or a cystic change [13]. Although there is no well-established treatment or prospective study results for angiosarcoma, radiation and surgery are recommended for localized lesions [3, 9]. When there is a high risk for the relapse of angiosarcoma, high-capacity radiation therapy above 50 Gy is recommended [9]. When metastatic, the primary treatment is cytotoxic chemotherapy, with the main drugs being doxorubicin, ifosfamide, and taxanes [14]. When a patient has a poor status or is elderly, monotherapy with a taxane-class drug is recommended [15]. The 5-year survival rate for angiosarcoma is as low as 35%. A poor prognosis is predicted for factors such as the primary site of the liver, a performance above 2 on the ECOG scale, and the existence of metastatic lesions at the time of diagnosis [10].
CONCLUSION
Angiosarcoma should be considered in the differential diagnosis of advanced-aged people presenting with hydropneumothorax and cystic lung lesions. Scalp lesions should be searched in the presentation of pneumothorax in angiosarcoma. Immunohistochemistry provides an indicator for the diagnosis of malignant pleural effusion in angiosarcoma.
CONFLICT OF INTEREST
The authors confirm that this article content has no conflict of interest.
ACKNOWLEDGEMENTS
Thanks to Ms. Haesoo Chang for the support of English revision.